Title : Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia.

Pub. Date : 2020 Jan

PMID : 31910380






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Somatic mutations of IDH1 are found in 7% to 14% of patients with AML; however, the patient in this study was the first patient with IDH1-mutated AUL treated with ivosidenib. ivosidenib isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens
2 Somatic mutations of IDH1 are found in 7% to 14% of patients with AML; however, the patient in this study was the first patient with IDH1-mutated AUL treated with ivosidenib. ivosidenib isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens
3 Targeted therapy using ivosidenib may represent an encouraging therapeutic option in patients with AUL and IDH1 mutations. ivosidenib isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens